Cytotherapy

Papers
(The median citation count of Cytotherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)
ArticleCitations
Editorial Board98
ESTABLISHING A NATIONAL REGULATORY POLICY AND FRAMEWORK FOR THERAPEUTIC USE OF CELL AND TISSUE THERAPIES IN SULTANATE OF OMAN.54
FAPα-TARGETED IMMUNOTHERAPY WITH SIBROTUZUMAB AND HIGH AFFINITY FC-RECEPTOR EXPRESSING NK92 CELLS: A PROMISING APPROACH TO REVERSE FIBROSIS53
CLINICALLY COMPLIANT MATRIX FOR HUMAN ES AND IPSC CULTURE FOR PRECLINICAL AND CLINICAL THERAPY41
OPTIMIZATION OF AUTOMATED SELECTION AND LENTIVIRAL VECTOR MEDIATED TRANSDUCTION OF MSC40
MICROPOROUS PARTICLE SCAFFOLDS FOR MESENCHYMAL STROMAL CELL EXPANSION AND ENHANCED IMMUNOMODULATORY FUNCTION39
ANALYSIS OF COLD CHAIN PROCESSES FOR INVESTIGATIONAL CELL THERAPY PRODUCT SHIPMENTS AND TRANSPORT BASED ON REAL-WORLD TEMPERATURE DATA37
Aims and Scope36
CARTAR WEB TOOL: A CASE STUDY UNVEILING PROMISING TARGETS FOR CHIMERIC ANTIGEN RECEPTOR THERAPIES IN COLORECTAL ADENOCARCINOMA36
SAMPLE TYPE, BUT NOT STORAGE DURATION, IMPACTS POST-THAW CD34 VIABILITY ON CORD BLOOD UNITS35
COMPARATIVE PROFILING OF MESENCHYMAL STEM CELL EXTRACELLULAR VESICLES FOR APPLICATION IN REGENERATIVE DERMATOLOGY32
EFFECTS OF STORAGE TEMPERATURE ON VITAL PARAMETERS OF CLINICAL GRADE CRYOPRESERVED MESENCHYMAL STEM CELL FINAL PRODUCT32
INVESTIGATING THE INTERPLAY BETWEEN GUT MICROBIOME, MONOCYTES/MACROPHAGES, AND OSTEOARTHRITIS32
INTER-DONOR VARIABILITY AND CELLULAR PROLIFERATION: THEIR IMPACT ON THE IMMUNOMODULATORY STRENGTH OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS IN T CELL-MEDIATED HEPATITIS31
ECTOPIC EXPRESSION OF CD39, A KEY REGULATOR OF THE PURINERGIC SIGNALING PATHWAY, INCREASED THE IMMUNOMODULATORY PROPERTIES OF MSC-DERIVED EXTRACELLULAR VESICLES31
SAFETY AND EFFICACY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL OF OCU400 MODIFIER GENE THERAPY FOR TREATMENT OF RETINITIS PIGMENTOSA29
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy28
International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-ba28
Clinical trial assessing the safety and efficacy of human bone marrow-derived allogeneic mesenchymal stem cell therapy for chronic active antibody-mediated rejection in kidney transplant recipients28
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity27
Repeated intravenous doses of human umbilical cord-derived mesenchymal stromal cells for bronchopulmonary dysplasia: results of a phase 1 clinical trial with 2-year follow-up27
Distinct effects of intravenous bone marrow-derived mesenchymal stem cell therapy on ischemic and non-ischemic lungs after ischemia-reperfusion injury27
Mesenchymal Stem/Stromal Cells: CELLULAR AGING SECRETES: A COMPARISON OF BONE MARROW DERIVED AND INDUCED MESENCHYMAL STEM CELLS AND THEIR SECRETOME OVER LONG TERM CULTURE27
Programmed spontaneously beating cardiomyocytes in regenerative cardiology26
Editorial Board26
Impact of Age and acute GVHD on Thymic Reconstitution Post-HCT: Insights from Multicenter Immune Monitoring of Pediatric and Young Adult Patients26
The Impact of Prior Immunotherapy on Composition of Apheresis Material for CAR T-cell Therapy in Patients with B-Cell Acute Lymphocytic Leukemia (B-ALL)25
MOUSE MESENCHYMAL STROMAL CELL POTENCY ASSAY IN CONTEXT OF USE IN ACUTE LUNG INJURY25
An innovative iPSC Reprogramming mRNA-LNP Kit for PBMC24
Enhancing Gene Transfer Efficiency in Viral and Non-Viral Vectors for Therapeutic Delivery24
Scalable Production of Hematopoietic Stem Cells and Microglia from iPSCs Using Stirred Tank Bioreactors for Consistent Cell Therapy Manufacturing24
The hyper-inflammatory ARDS microenvironment enhances MSC reparative capacity in a pre-clinical model of acute lung inflammation23
Classification of Foreign Materials Found in Mesenchymal Stem/Stromal Cell Product Manufacturing23
ACOUSTIC BEADS: A NOVEL METHOD FOR CELL SORTING USING ACOUSTOPHORESIS23
Improving single cell multiomic analysis of T and B cells with innovations enhancing cost-effectiveness and data quality23
CUTTING-EDGE LIPID-BASED MICROBUBBLE PLATFORM: ENHANCING CELL SORTING22
A Narrative Review of Islamic Bioethics and Regenerative Medicine: The Case of Amniotic Fluid Mesenchymal Stem Cells22
Thymic Regulatory NK Cells: A Therapeutic Target for Restoring Immune Balance in Chronic Graft-Versus-Host Disease (cGVHD).22
Evaluating CAR T cell therapy processing with the Sefia™ expansion system using commercially available cell culture media22
Elevating MSC-EV Analysis: Development and Qualification of a CD73 Bioactivity Assay21
HYDROGEL MICROPARTICLE-BASED ARTIFICIAL ANTIGEN-PRESENTING CELL FOR EFFICIENT EXPANSION AND REACTIVATION OF NK CELLS EX VIVO.21
Streamlined Production of Tumor-Associated Antigen-Specific T Cells (TAAT) from Antigen-Naïve Donors in a GREX Device Using Autologous Monocyte-Derived Dendritic Cells (MoDC) Manufactured in the Same 21
Hematopoietic Stem/Progenitor Cells and Engineering: HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC20
Initial Experience Implementing a Structured Review Service for Non-GLP Study Data Intended to Support Regulatory Submissions at an Academic Institution20
Immunotherapy: EXPANSION AND PROCESSING OF A CLINICALLY RELEVANT NUMBER OF NK CELLS20
Immunotherapy: B7H3-CAR NK CELLS AND DNR CO-TRANSDUCED NK SHOWS MAINTAIN THEIR POTENCY AGAINST TGF-B MEDIATED IMMUNE SUPPRESSION20
Process Development and Manufacturing: IMPROVED DOWNSTREAM VIRUS PURIFICATION YIELD USING EXCIPIENT-GRADE RECOMBINANT ALBUMIN, EXBUMIN20
GENERATION AND OPTIMIZATION OF ANTI-CD19 CAR-T CELL FOR LEUKEMIA IMMUNOTHERAPY19
CONSTRUCTION OF DEAD-CAS9 MACHINERY FOR ACTIVATION OF ENDOGENOUS NEUROPROTECTIVE TRANSCRIPTION FACTOR MAX IN VITRO19
Immunotherapy: TARGETING EWING SARCOMA (ES), OSTEOSARCOMA (OS) AND NEUROBLASTOMA (NB) WITH ANTI-MCAM CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED NATURAL KILLER (NK) CELLS19
A Simple Approach to Monitor the Cryostorage of Hematopoietic Stem Cells19
Mesenchymal Stem/Stromal Cells: TARGETING ENDOGENOUS MESENCHYMAL STROMAL CELL RESPONSE TO INTERFERONγ IN SJÖGREN’S19
Exosomes/EVs: REAL-TIME BIOPROCESS MONITORING FOR LARGE-SCALE PRODUCTION OF MESENCHYMAL STROMAL CELL-DERIVED EXTRACELLULAR VESICLES18
Marrow changes and reduced proliferative capacity of mesenchymal stromal cells from patients with “no-option” critical limb ischemia; observations on feasibility of the autologous approach from a clin18
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway18
Mesenchymal Stem/Stromal Cells: EVALUATION OF SCALABLE ATTACHMENT-DEPENDENT EXPANSION SYSTEM FOR MESENCHYMAL STEM CELLS IN XENO- AND SERUM-FREE MEDIA18
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF ICH Q2 (R1) COMPLIANT IMMUNOPOTENCY ASSAY MEASURING MESENCHYMAL STROMAL CELLS MEDIATED T-CELL INHIBITION18
Process Development and Manufacturing: CAR-T CELLS MANUFACTURED VIA POSITIVE AND NEGATIVE IMMUNOMAGNETIC T CELL SELECTION SHOW DIFFERENT TUMOR KILLING RATES, CYTOKINE PROFILES, AND γδ T CELL OUTPUT18
Immunotherapy: MULTI-CENTER GAMMA-DELTA T CELL CLINICAL TRIAL PRODUCT IDENTIFICATION USING NEW PRODUCT ATTRIBUTE AND NEW CODES FOR ISBT 128 LABELING18
ISCT survey on hospital practices to support externally manufactured investigational cell-gene therapy products17
Mesenchymal Stem/Stromal Cells: ICE RECRYSTALLIZATION INHIBITOR INCREASES POST-THAW FUNCTIONAL CAPACITY OF BONE MARROW AND UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS17
Mesenchymal Stem/Stromal Cells: HYPERINFLAMMATION AND IMMUNE CELL DYSREGULATION IN C7 HYPOMORPHIC MOUSE MODEL OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA: IMMUNE AND INFLAMMATION MODULATION BY HUMAN17
Process Development and Manufacturing: CRYOPRESERVATION METHOD OPTIMIZATION FOR PLACE-OF-CARE MANUFACTURING OF A FIRST IN HUMAN TRI-SPECIFIC CAR T-CELL THERAPY PRODUCT FOR LYMPHOID MALIGNANCIES17
THERAPEUTIC BENEFIT OF HUMAN WHARTON’S JELLY MESENCHYMAL STROMAL CELLS IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS17
Exosomes/EVs: Late Breaking Abstract: EFFECTS OF AMNIOTIC FLUID DERIVED EXTRACELLULAR VESICLE BIOLOGIC ON T CELL PROLIFERATION AND ACTIVATION17
Process Development and Manufacturing: VALIDATION OF THE MANUFACTURING OF AUTOLOGOUS MUC-1 ACTIVATED T CELLS FOR A PHASE I DOSE ESCALATION TRIAL FOR PATIENTS WITH MULTIPLE MYELOMA17
Mesenchymal Stem/Stromal Cells: HUMAN MSCS REDUCE INFLAMMATION AND PROMOTE REPAIR IN SEVERE HOUSE DIST MITE INDUCED ALLERGIC AIRWAY DISEASE DRIVEN BY MACROPHAGE MIGRATION INHIBITORY FACTOR17
Process Development and Manufacturing: MINIMIZING PARTICULATE CONTAMINATION IN SINGLE-USE SYSTEMS FOR BIOPHARMACEUTICAL AND PHARMACEUTICAL INDUSTRIES16
GENERATION OF HUMAN INDUCED PLURIPOTENT STEM CELL LINES DERIVED FROM TWO BRAZILIAN PATIENTS WITH HUTCHINSON-GILFORD PROGERIA SYNDROME CARRYING C.1824 C>T MUTATION16
Process Development and Manufacturing: A NEEDLE-BASED AUTOSAMPLER FOR BIOREACTOR CELL MEDIA COLLECTION16
Mesenchymal Stem/Stromal Cells: MULTIPOTENT MESENCHYMAL STROMAL CELLS FROM PATIENTS WITH SYSTEMIC SCLEROSIS HAVE PRESERVED CLONOGENICITY, IMMUNOPOTENCY AND IN VITRO ANTIFIBROTIC EFFECTS16
iPSC: IDENTIFICATION AND VALIDATION OF VENTRICULAR-SPECIFIC SURFACE MARKER FOR HUMAN PLURIPOTENT STEM CELLS-DERIVED CARDIOMYOCYTES16
THE EFFECT OF THE PRO-APOPTOTIC RHTRAIL PROTEIN IN THE PRESENCE OR ABSENCE OF THE COMBINATION WITH THE HSV-1 VIRUS IN HEAD AND NECK TUMOR LINES16
Immunotherapy: APPLICATIONS OF IMMUNE PROFILING: QUANTITATIVE PHENOTYPIC ANALYSIS OF ALS PATIENTS RECEIVING MSC THERAPY16
Aims and Scope16
Mesenchymal Stem/Stromal Cells: TRANSFECTION OPTIMIZATION FOR GENERATING CLINICAL GRADE IL-10 mRNA ENGINEERED MSCS16
Mesenchymal Stem/Stromal Cells: SUBCUTANEOUS DELIVERY OF ALLOGENEIC INTERFERON-γ LICENSED BONE MARROW DERIVED MESENCHYMAL STROMAL CELL (IFN-γ MSC) FOR THE TREATMENT OF TRAUMATIC BRAIN INJURY (TBI)16
PREPARATION OF MUSCLE-DERIVED STEM CELLS SPHEROIDS IN A SCAFFOLD-FREE MICROMOLDED HYDROGEL MAINTAINING THEIR MYOGENIC POTENTIAL16
iPSC: ENGINEERING 3D MICRO-COMPARTMENTS FOR HIGHLY EFFICIENT AND SCALE-INDEPENDENT EXPANSION OF HUMAN PLURIPOTENT STEM CELLS IN BIOREACTORS16
Tissue Engineering: AUTOLOGOUS 3D NEURAL IMPLANTS FOR SPINAL CORD INJURY15
Editorial Board15
Mesenchymal Stem/Stromal Cells: CELL CULTURE MEDIA (CCM) AND/OR LICENSING SIGNIFICANTLY AFFECTS THE GENE EXPRESSION, SECRETOME AND IMMUNE CELL INTERACTION CAPACITY OF UMBILICAL CORD DERIVED MESENCHYMA15
Mesenchymal Stem/Stromal Cells: CAN PRIMING APPROACHES IMPROVE THE IMMUNOREGULATORY CAPABILITY OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELLS TO TREAT PANCREATIC CANCER?15
Welcome to ISCT 202315
Immunotherapy: A 3D VASCULARIZED MICROFLUIDIC MODEL OF THE TUMOUR MICROENVIRONMENT FOR ASSAYING PSC DERIVED CAR-T CELL FUNCTION15
A comprehensive review of quantum bioreactor cell manufacture: Research and clinical applications15
Embryonic, Organ and Other Tissue Specific Stem Cells: EXPLORING THE ANTI-TUMOR EFFECTS OF HUMAN WHARTON’S JELLY DERIVED MESENCHYMAL STEM CELL SECRETOME ON PANCREATIC DUCTAL ADENOCARCINOMA CELLS IN CO15
Process Development and Manufacturing: ONE YEAR FROM VECTOR TO BEDSIDE: RAMPING UP A SUCCESSFUL IN-HOUSE CAR T-CELL MANUFACTURING PROGRAM USING A NOVEL TRI-SPECIFIC CAR T-CELL THERAPY FOR LYMPHOID MAL15
Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies15
An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells (MSC) Committee perspectives on International Standards Organization/Technical Committee 276 Biobanking Standards for bone 14
Consensus International Council for Commonality in Blood Banking Automation–International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin 14
Table of Contents14
“Combined synergistic effects of concentrated growth factors and adipose-derived mesenchymal stem cells on regeneration of induced mandibular defects in rabbits”14
Alternative target recognition elements for chimeric antigen receptor (CAR) T cells: beyond standard antibody fragments14
Human cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase14
Impact of FLT3 internal tandem duplication and NPM1 mutations in acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation14
Secretome of bone marrow mesenchymal stromal cells cultured in a dynamic system induces neuroprotection and modulates microglial responsiveness in an α-synuclein overexpression rat model14
EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS13
Development of an induced pluripotent stem cell–specific microRNA assay for detection of residual undifferentiated cells in natural killer cell therapy products13
Role of mesenchymal stromal cells derivatives in diabetic foot ulcers: a controlled randomized phase 1/2 clinical trial13
Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions13
Predicting chimeric antigen receptor apheresis process volume13
Safety and Efficacy of High-Dose Memory CD45RO+ Donor Lymphocyte Infusion in Pediatric Recipients after Hematopoietic Stem Cell Transplantation13
Advancing Wound Healing with Pre-Activated Umbilical Cord Mesenchymal Stem Cell Secretome12
Regulatory advancements in Japan's conditional and time-limited approval scheme for regenerative medical products: the first guidance on the approval scheme and the second review for full approval of 12
PROCESS DEVELOPMENT FOR SCALABLE ALLOGENEIC CAR-T MANUFACTURING IN STIRRED-TANK BIOREACTORS: PERFUSION OPTIMISATION, MULTI-LITRE SCALE-UP AND AUTOMATED HARVESTING12
Investigating MSC immune suppressive function with quantitative phase microscopy and single-cell spatial lipidomics12
Phospholipids in small extracellular vesicles: emerging regulators of neurodegenerative diseases and cancer12
Therapeutic Potential of First-Trimester Human Umbilical Cord Perivascular Cells in Mitigating Age-Related Muscle Dysfunction in a Natural Mouse Model of Aging12
Chimeric STAR receptors enable high-sensitivity TCR-negative CD8αβ- CD3-positive T-cell development from human-induced pluripotent stem cells12
A report on the International Society for Cell & Gene Therapy 2022 Scientific Signature Series, “Therapeutic advances with native and engineered human extracellular vesicles”12
THE ASSESSMENT OF WOMEN'S EDUCATION IN MEXICO ON CORD BLOOD (CB) BANKING AND ETHICAL IMPLICATIONS11
Real World Experience of a Single-Center Tumor Infiltrating Lymphocyte (TIL) Melanoma Therapy Program: primary referral to TIL infusion (Brain to Vein)11
PRE-CLINICAL CHARACTERIZATION OF ALLOCETRATM; A NOVEL MACROPHAGE REPROGRAMMING CELL THERAPY, FOR INTRA-ARTICULAR TREATMENT IN OSTEOARTHRITIS11
Advancing CAR-NK Cell Engineering by Overcoming Transduction Challenges11
Particulate Management in Bioprocessing: Challenges, Strategies, and Solutions11
LONG-TERM TOLERANCE TO LEYDIG CELL TRANSPLANTATION WITH LOCALIZED TREG IMMUNOMODULATION USING THE NANOLYMPH PLATFORM11
Dual-CAR NK cells targeting PD-L1 and ErbB2/HER2 eliminate solid tumor cells and prevent immune escape due to antigen loss11
Key Strategies for Successful Equipment Qualification in Cell Therapy GMP11
A Multi-Donor Characterization of Degradable Microscaffolds for Therapeutic T Cell Manufacturing11
EXPLORING INNOVATIVE BIOREACTOR SYSTEM FOR END-TO-END T CELL MANUFACTURING11
AdoShell®, a non-fibrotic encapsulation system for cell delivery10
Detection of very small embryonic-like stem cells (VSELs) in the peripheral blood of rabbits subjected to induced retinal vein occlusion as a proposed early detection tool for the disease10
Challenging immunophenotyping of patients with sickle cell disease adversely affects gene therapy product manufacturing – case reports.10
THE MULTI POTENTIALS OF PLACENTA CHORIODECIDUAL MEMBRANES-DERIVED-MSCS (PCMSCS) FOR DECIDUALIZATION AND ANGIO-MYOGENESIS10
BIOMATERIAL-ENABLED MACROPHAGE CELL THERAPY VIA DEXAMETHASONE-LOADED MICROPARTICLES FOR REGENERATIVE MEDICINE10
ENEPC-CLI-01- A PHASE 2 DOUBLE BLIND PLACEBO CONTROLLED STUDY FOR AUTOLOGOUS BGC-101, ENRICHED ENDOTHELIAL PROGENITOR CELLS, FOR CRITICAL LIMB THREATENING ISCHEMIA10
Accelerating sterility testing: Symcel calScreener+ achieves results in <3 days with direct inoculation in non-destructive and continuous monitoring system10
IMPLEMENTING CUSTOM PARTICLE SWARM-DIFFERENTIAL EVOLUTION OPTIMIZATION (PSODE) FOR GFP PLASMID DNA TRANSFECTION IN JURKAT AND PRIMARY T CELLS10
ABSOLUTE QUANTIFICATION OF GENOMIC TARGETS FOR CELL COUNTING USING DROPLET DIGITAL PCR10
Results of the Phase I/IIb EXCELLENT trial evaluating the safety and efficacy of transendocardial injection of expanded autologous CD34+ cells in patients with recent myocardial infarction10
IMPROVED UNDERSTANDING OF CELL FATE USING A KIDNEY NORMOTHERMIC MACHINE PERFUSION MODEL10
AUTOANTIGEN-SPECIFIC REGULATORY T CELLS HALT THE PROGRESSION OF LUPUS NEPHRITIS10
BACK TO BASICS: A SCIENTIFIC AND ECONOMIC EVALUATION OF ADHERENT AND SUSPENSION PROCESSING FOR AAV AT SCALE10
INSIGHTS INTO SPATIOTEMPORAL DYNAMICS OF ALLOREACTIVE T CELL RESPONSE WITH γMSCS ADMINISTRATION10
Gene Editing/Gene Therapies: EVALUATION OF TRANSFECTION REAGENTS FOR HIGH TITER LENTIVIRUS PRODUCTION IN THE ICELLIS NANO BIOREACTOR9
IMMUNOMODULATORY POTENTIAL OF ENHANCED MSC-DERIVED EXTRACELLULAR VESICLES9
MANUFACTURE OF A BANK OF “OFF-THE-SHELF” CD30.CAR-EBVSTS FOR THE TREATMENT OF LYMPHOMA9
Increasing access to transplantation through telemedicine and patient navigation9
Author index9
BIOPOTENCY AND SURROGATE ASSAYS TO VALIDATE IMMUNOMODULATORY POTENCY OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM/STROMAL CELLS9
Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee9
A NEW ERA OF BIOLOGICS: THE ROLE OF SOUTH KOREA's REGULATORY SCIENCE CENTER IN ENSURING LONG TERM SAFETY9
The donor genetic determinant of human thymopoiesis rs2204985 is associated with acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients9
MULTIOMIC PROFILING OF EX VIVO EXPANDED CD45 (+)CD34(BRIGHT) CD38(-) CD90(+) CD49F(+)CELLS REVEALS NOVEL PATHWAYS FOR THE LONG-TERM MAINTENANCE OF HEMATOPOIETIC STEM AND PROGENITOR CELLS9
Mesenchymal Stem/Stromal Cells: MSC AND THEIR ISOLATED MITOCHONDRIA IMPROVE THE REGENERATION OF MICE CUTANEOUS SURGICAL WOUNDS BY IN-SITU INJECTION9
NON-VIRAL GENOME EDITING IN HEMATOPOIETIC STEM CELLS (HSCS) FOR CELL-THERAPY APPLICATIONS - FROM DISCOVERY TO MANUFACTURING9
Impact of mesenchymal stromal/stem cell infusions on circulating inflammatory biomarkers in COVID-19 patients: analysis of a phase I-IIa trial9
MESENCHYMAL STROMAL CELLS EXPRESSING DEGRON-HPV16 E5 AS A NOVEL CERVICAL CANCER VACCINE9
Exosomes/EVs: MSC-DERIVED EVS ATTENUATE ATOPIC DERMATITIS BY SUPPRESSING INFLAMMATION AND PROMOTING EPIDERMAL BARRIER REPAIR9
Mesenchymal Stem/Stromal Cells: TRANSCRIPTIONAL TARGETS OF TWIST1 IN HUMAN MESENCHYMAL STEM/STROMAL CELLS8
Immunotherapy: ALLOCETRA-OTS, AN EARLY APOPTOTIC CELLULAR THERAPY SYNERGIZE WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY OR IMMUNE CHECK POINT INHIBITOR AGAINST PERITONEAL SOLID TUMOR8
Mesenchymal Stem/Stromal Cells: IND CMC COMPATIBLE PURITY AND IDENTITY ASSESSMENT OF IFNγ-STIMULATED BONE MARROW SOURCED MESENCHYMAL STROMAL CELLS FOR A PHASE I CLINICAL TRIAL8
Process Development and Manufacturing: HIGH DENSITY BATCH CULTURES OF WJ-HMSCS IN STIRRED-TANK BIOREACTORS EQUIPPED WITH THE NOVEL BACH IMPELLER8
Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies8
Mesenchymal Stem/Stromal Cells: UPFRONT USE OF ALLOGENEIC CYTO-MSC IMPROVES RESPONSE AND SURVIVAL RATES IN PATIENTS WITH ACUTE GVHD: AN INTERIM ANALYSIS OF ONGOING PHASE I/II MULTICENTER CLINICAL STUD8
Mesenchymal stromal cells regulate THP-1–differentiated macrophage cytokine production by activating Akt/mammalian target of rapamycin complex 1 pathway8
Establishing a robust chimeric antigen receptor T-cell therapy program in Australia: the Royal Prince Alfred Hospital experience8
Mesenchymal Stem/Stromal Cells: INTRAVENOUS INJECTION OF XENOGENEIC MITOCHONDRIA ISOLATED FROM HUMAN FIBROBLAST AND MESENCHYMAL STEM/ STROMAL CELLS (MSC) ARE DETECTED IN THE HEART, INDUCE PGC-1α AND I8
Tissue Engineering, Embryonic, Organ and Other Tissue Specific Stem Cells: GRAPHENE DERIVATES FOR BONE TISSUE REGENERATION8
Mesenchymal Stem/Stromal Cells: PATIENT RESPONSES TO MESENCHYMAL STROMAL CELL (MSC) THERAPY IN OSTEOARTHRITIS ARE ASSOCIATED WITH DIFFERENTIAL CLINICAL PHENOTYPES, MOLECULAR ENDOTYPES, AND MSC CRITICA8
Mesenchymal Stem/Stromal Cells: EVALUATION OF THE EFFECT OF MEDIUM COMPOSITION ON THE PHENOTYPIC AND FUNCTIONAL ATTRIBUTES OF MESENCHYMAL STROMAL CELLS8
Subscription information8
Regulatory Affairs, Quality Systems, Policy, and Ethics: TESTING CELL THERAPY AND BIOPRODUCTION SAMPLES USING THE BIOFIRE® MYCOPLASMA MOLECULAR LAB IN A POUCH SYSTEM8
IMMUNOMODULATORY POTENTIAL OF EXTRACELLULAR VESICLES DERIVED FROM MESENCHYMAL STEM CELLS OBTAINED BY ULTRAFILTRATION AND ULTRACENTRIFUGATION8
Immunotherapy: ACCELERATING DEVELOPMENT AND IMPROVING ACCESS TO CAR- AND TCR-ENGINEERED T CELL THERAPY IN EUROPE8
Immunotherapy: ANTI-GD2 CAR T CELLS AGAINST SMALL CELL LUNG CANCER8
Gene Editing/Gene Therapies: GDA-501 HER-2 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS: DUAL CYTOTOXICITY IN SOLID TUMORS MEDIATED VIA HER2 AND TRAIL8
Regulatory Affairs, Quality Systems, Policy, and Ethics: EVALUATION OF PERCENTAGE CHANGE IN PRE-DONATION AND POST-DONATION LABORATORY VALUES AFTER REPEATED (MNC), APHERESIS DONATIONS8
Gene Editing/Gene Therapies: ENHANCING ANTI-OXIDATION OF MESENCHYMAL STROMAL/STEM CELLS USING CRISPR/CAS9 FOR INFLAMMATORY AND ISCHEMIC-REPERFUSION INJURY7
Gene Editing/Gene Therapies: A NOVEL WEIGHT-BASED APPROACH TO DETERMINE CELL TYPE SPECIFICITY FROM SINGLE CELL DATASETS7
STERILITY SAMPLING OF CELL, GENE, AND TISSUE THERAPY PRODUCTS (ATMPs)7
CD73 activity of mesenchymal stromal cell-derived extracellular vesicle preparations is detergent-resistant and does not correlate with immunomodulatory capabilities7
The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy7
Mesenchymal Stem/Stromal Cells: HUMAN MESENCHYMAL STEM CELL THERAPY IN SEVERE COVID-19 PATIENTS: 2-YEAR FOLLOW-UP RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL7
Scientific venturing for early-stage professionals (ESPs), a key concept in the innovation ecosystem7
Allogeneic transplantation after immunotherapy for relapsed/refractory non-Hodgkin lymphoma: a comparison with a historical cohort7
Mesenchymal Stem/Stromal Cells: SINGLE-CELL TRANSCRIPTOMICS COMPARISON OF CELL THERAPEUTICS IN OSTEOARTHRITIS7
Prognostic factors in haploidentical transplantation with post-transplant cyclophosphamide for acute myeloid leukemia7
Immunotherapy: CONVERTING IMMUNOLOGICALLY “COLD” MICROSATELLITE-STABLE COLORECTAL CANCER TO “HOT” BY DNA METHYLTRANSFERASE INHIBITOR AND RADIATION TO ENHANCE THERAPEUTIC EFFICACY7
Tissue Engineering: DEVELOPMENT OF A TISSUE-ENGINEERED PRODUCT FOR GINGIVAL RECESSION7
Graft-versus-host disease is associated with skewed γδ T-cell clonality after umbilical cord blood transplantation in children with nonmalignant diseases7
CRISPR ENGINEERING OF ARMORED CAR T CELLS ENABLES TUMOR-RESTRICTED PAYLOAD DELIVERY WITH ENHANCED SAFETY AND EFFICACY7
Impact of lower concentrations of dimethyl sulfoxide on cryopreservation of autologous hematopoietic stem cells: a systematic review and meta-analysis of controlled clinical studies7
Immunotherapy: THE BTLA-HVEM AXIS IS A CRUCIAL IMMUNE CHECKPOINT OF T CELL IMMUNOTHERAPIES FOR CANCER7
Process Development and Manufacturing: SUPERIOR EXPANSION OF γδ T-CELL SUBSETS FOR SOLID TUMOR T-CELL THERAPY USING A CHEMICALLY-DEFINED NON-ANIMAL ORIGIN SERUM-FREE CULTURE MEDIUM7
EFFECTS OF IGF-1-OVEREXPRESSING MESENCHYMAL STROMAL CELL TRANSPLANTATION IN A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS7
Subscription information7
Outcomes following hematopoietic cell transplantation for children, adolescents and young adults with relapsed acute lymphoblastic leukemia7
iPSC: THE IPS DERIVED MESENCHYMAL STEM CELLS AMELIORATED LIVER FIBROSIS AND LIVER FATTY DEPOSITION IN NAFLD/MAFLD-RELATED CIRRHOTIC MICE7
Reduced dimethyl sulfoxide concentrations successfully cryopreserve human hematopoietic stem cells with multi-lineage long-term engraftment ability in mice7
Mesenchymal Stem/Stromal Cells: SUSPENSION CULTURE OF HUMAN MESENCHYMAL STROMAL CELLS ON DISSOLVABLE MICROCARRIERS IN AN ANIMAL COMPONENT FREE CULTURE SYSTEM7
Immunotherapy: PHASE I CLINICAL TRIAL OF ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN EXPANDED T CELLS TO TARGET LEUKEMIA RELAPSING AFTER ALLOGENEIC HLA-MATCHED TRANSPLANTATION7
ACTIVATION, EXPANSION, AND CULTURE OF HUMAN T CELLS INCORPORATING IMMUNOCULTTM CGMP-COMPLIANT ANCILLARY REAGENTS7
MICROFLUIDICS IMPROVES LENTIVIRUS TRANSDUCTION EFFICIENCY7
Mesenchymal Stem/Stromal Cells: THE INTERFERON-GAMMA-INDOLEAMINE 2,3-DIOXYGENASE 1 (IFN-G-IDO1) AXIS IS NOT INVOLVED IN THE MSC-MEDIATED IMMUNOSUPPRESSION OF ACTIVATED T CELL PROLIFERATION7
2023 Gene Therapy Mini-Series7
The emerging promise of induced pluripotent stem cells in clinical studies: a systematic scoping review of the literature and registered clinical trials7
Mesenchymal Stem/Stromal Cells: EFFECTS OF COLD STORAGE ON MITOCHONDRIAL BIOENERGETICS AND PROTEIN IN HUMANMSCS7
Filling the gap: the workforce of tomorrow for CGT manufacturing as the sector advances7
Mesenchymal Stem/Stromal Cells: CELL CERAMTM ASSOCIATED WITH HUMAN LEVATOR VELI PALATINI MUSCLE STROMAL CELLS TO BONE RECONSTRUCTION IN CRANIOFACIAL SYNDROMES7
From Bench to Bedside – ongoing Clinical Development in Organoids and cell Therapy in Europe6
Process Development and Manufacturing: OPTIMIZATION OF CHONDRON RECOVERY PROCEDURE FROM AUTOLOGOUS CARTILAGE OF THE FEMOROACETABULAR JOINT6
Hematopoietic Stem/Progenitor Cells and Engineering: A NEW METHOD FOR THE AUTOMATED ENUMERATION AND ANALYSIS OF CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS BY FLOW CYTOMETRY6
"ONE POT’" PRODUCTION OF CHIMERIC ANTIGEN RECEPTOR T CELLS IN A NOVEL BIOREACTOR DESIGN6
Advancing the Development of Innovative Human Platelet-Derived Exosomes for Enhanced Therapeutic Applications6
Regeneration-associated cells and their secreted extracellular vesicles are advantageous in promoting the healing of ischemic tissues6
Comparative Analysis of Total Antibody Titer and Neutralizing Antibody Titer: Correlation and Implications for AAV-Based Gene Therapies.6
Immunomodulatory Effects of Human Dental Pulp Stem Cells on Monocyte Polarization via Efferocytosis6
Ex-vivo expanded CD34+ cell transplantation alleviates fibrotic liver injury via innate immune modulation in metabolic dysfunction-associated steatohepatitis mice6
Cell and gene therapy workforce development: the role of the International Society for Cell & Gene Therapy (ISCT) in the creation of a sustainable and skilled workforce in Europe6
A PLATFORM FOR THE ISOLATION AND CHARACTERIZATION OF EXTRACELLULAR VESICLES - EXPLORING A COMPREHENSIVE COLLECTION OF HUMAN EV6
MINIMALLY INVASIVE TUMOR TISSUE PROCUREMENT IS FEASIBLE FOR CLINICAL MANUFACTURING OF OBX-115 ENGINEERED TUMOR-INFILTRATING LYMPHOCYTES (TIL)6
AUTOLOGOUS T CELL APHERESIS IS SUCCESSFUL ACROSS PEDIATRIC PATIENT POPULATIONS WITH HEMATOLOGIC MALIGNANCIES, SOLID TUMORS, AND BRAIN TUMORS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS6
Mesenchymal Stem/Stromal Cells: HIGH-DIMENSIONALL MULTI-OMICS COMPARISON OF CELLS IN BONE MARROW REVEALED ALTERATIONS TO IMMUNE CELLS IN OSTEOARTHRITIS6
Coupling programmed cell death 1-positive tumor-infiltrating T cells with anti-programmed cell death 1 antibody improves the efficacy of adoptive T-cell therapy6
Compliance and cost control for cryopreservation of cellular starting materials: An industry perspective6
Adjustment of Apheresis Instrument Collection Parameters Improves Quality of HPC(A) Products6
Development of a High Yield/High Purity Exosome Downstream Process that Retains Critical Quality Attributes6
ENHANCING HUMAN MESENCHYMAL STEM CELL MICROCARRIER CULTURE THROUGH PERFUSION PROCESS DEVELOPMENT6
Subscription information6
COMPARATIVE CHARACTERIZATION OF HUMAN DERMAL MESENCHYMAL STROMAL CELLS FROM DIFFERENT ANATOMICAL LOCATIONS AND ACROSS THE LIFESPAN6
Integrating cell confinement in a perfusion bioreactor improves iMSC extracellular vesicle production and potency6
G-CSF-primed Allogenic Bone Marrow-derived Mesenchymal Stem Cells Induce Suppression of Clonal Proliferation of BCR/ABL positive Chronic Myeloid Leukmemia6
Regulatory Considerations for the Review System of Unproven Stem Cell Therapies in Japan6
Feeder cell-free production and characterization of high yields of human NK cells for CAR-NK therapies using human platelet lysate6
Immunotherapy: SIGNALING DOMAINS, 41BB AND CD28, MEDIATE DISTINCT MOLECULAR DYNAMICS AT THE IMMUNE SYNAPSE THAT INFLUENCE CAR T CELL KILLING BEHAVIOR6
Living medicines: Training before handling6
MACROMOLECULAR CROWDING IN XENO-FREE MESENCHYMAL STROMAL CELL CULTURES FOR THE DEVELOPMENT OF TISSUE ENGINEERED MEDICINES - CHALLENGING THE STATUS QUO6
Study of DMSO exposure time on the Viability of Cryopreserved Cord Blood Units6
Quantitative Predictive Cellular Analytics Driving Improvements in Advanced Therapy Development and Manufacturing6
Subscription information6
The dual role of PPARβ/δ nuclear receptor in MSC immunomodulatory and pro-reparative capacity in a model of acute lung inflammation6
Label-free, single-cell quantification of granulocyte macrophage progenitors from brightfield imaging6
Aims and Scope6
INVESTIGATING THE ADVANCEMENTS IN MESENCHYMAL STEM CELLS AND THEIR SECRETOME: UNVEILING THE POTENTIAL FOR FACIAL REJUVENATION6
MULTIOMIC ANALYSIS OF γMSC-SUPPRESSED ALLOREACTIVE T CELLS6
Mesenchymal Stem/Stromal Cells: LOCAL MANUFACTURING PROCESSES CONTRIBUTE TO VARIABILITY IN HUMAN MESENCHYMAL STROMAL CELL (MSC) EXPANSION WHILE GROWTH MEDIA SUPPLEMENTS CONTRIBUTE TO VARIABILITY IN GE5
Process Development and Manufacturing: ESTABLISHING CELL VIABILITY MEASUREMENTS THAT PREDICT PROLIFERATIVE CAPACITY IN A MODEL SYSTEM5
Process Development and Manufacturing: C3P3-G3 ARTIFICIAL EXPRESSION SYSTEM FOR HIGH PERFORMANCE LENTIVIRUS PRODUCTION WITH IMPROVED PREDICTED BIOSAFETY5
Exosomes/EVs: GROWTH MEDIA CONDITIONS INFLUENCE THE SECRETION ROUTE AND RELEASE LEVELS OF ENGINEERED EXTRACELLULAR VESICLES5
Immunotherapy: NK CELL EXPANSION USING SCALE UP BIOREACTORS FOR CELL THERAPY5
Exosomes/EVs: MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES: A NEW TREATMENT PARADIGM FOR SOLD ABDOMINAL ORGAN TRANSPLANT PATIENTS WTIH ALLOGRAFT FAILURE AND GRAFT VERSUS HOST DISEASE5
Tissue Engineering: AUTOFLUORESCENCE IMAGING IDENTIFIES KEY SUBSTRATE PROPERTIES TO SUPPORT STEM CELL-DERIVED CARDIOMYOCYTE DIFFERENTIATION5
Process Development and Manufacturing: CHALLENGES AND SOLUTION FOR PERFORMANCE VALIDATION OF EM AUTOMATION5
VIABILITY, DIFFERENTIATION PROFILE AND GENIC EXPRESSION OF UMBILICAL CORD BLOOD HEMATOPOIETIC PROGENITOR CELLS CULTURED ON PLA/COL/HA/MSC-WJ CONSTRUCTS AS AN EX VIVO EXPANSION STRATEGY5
Mesenchymal Stem/Stromal Cells: ROLE OF REACTIVE OXYGEN SPECIES IN SUPPRESSION OF ALLOREACTIVE T-CELLS BY INTERFERON-GAMMA PRIMED-MESENCHYMAL STROMAL CELLS5
Immunotherapy: INHOUSE MANUFACTURING OF CAR-T CELLS: MAKING QUALITY CAR-T CELL THERAPY MORE ACCESSIBLE TO THE GENERAL PUBLIC5
Process Development and Manufacturing: EFFECT OF DONOR AND METHOD VARIABILITY ON BIOMANUFACTURING PROCESS ESTABLISHMENT5
A machine-learning model that incorporates CD45 surface expression predicts hematopoietic progenitor cell recovery after freeze–thaw5
0.036875009536743